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Abstract 
Natural killer (NK) cells specialize in killing virally infected- or tumor cells and are part of the innate immune sys-
tem. The activational state of NK cells is determined by the balance of incoming activating and inhibitory signals 
mediated by receptor-ligand binding with the target cell. These receptor-ligand bonds mainly consist of the killer 
immunoglobulin-like receptors (KIR), which are expressed at the cell surface of NK cells, and their ligands: the highly 
variable human leukocyte antigen -class I molecules (HLA). Absence of an inhibitory receptor-ligand bond lowers the 
NK cell activation threshold, whereas an activating receptor-ligand bond stimulates the cell, potentially overcoming 
this threshold and triggering NK cell activation. NK cells influence the course of infection as well as the acquisition 
of HIV-1. Several lines of evidence relate the activating NK cell receptor KIR3DS1, in the presence or absence of its 
putative ligand HLA-Bw4, with slower disease progression as well as resistance to HIV-1 infection. Overall, resistance 
to HIV-1 infection predominantly correlates with activating KIR/HLA profiles, consisting of e.g. activating KIRs, group B 
haplotypes, or inhibitory KIRs in absence of their ligands. Such a conclusion is less evident for studies of HIV-1 disease 
progression, with studies reporting beneficial as well as detrimental effects of activating KIR/HLA genotypes. It is 
likely that KIR/HLA association studies are complicated by the complexity of the KIR and HLA loci and their mutual 
interactions, as well as by additional factors like route of HIV exposure, immune activation, presence of co-infections, 
and the effect of anti-HIV-1 antibodies. One newly discovered NK cell activation pathway associated with resistance 
to HIV-1 infection involves the presence of an iKIR/HLA mismatch between partners. The absence of such an iKIR/
HLA bond renders donor-derived allogeneic HIV-1 infected cells vulnerable to NK cell responses during HIV-1 trans-
mission. Therefore, theoretically, HIV-1 would be eliminated before it has the chance to infect the autologous cells in 
the recipient. While this “alloreactive” NK cell mechanism is especially relevant to HIV transmission in monogamous 
couples, it would be interesting to investigate how it could influence resistance to HIV in other settings. The objective 
of this review is to summarize the knowledge about these autologous and alloreactive NK cell responses with regard 
to HIV-1 outcome.
Keywords: HIV-1, Natural killer cells, KIR, HLA, Protection, Allogeneic
© 2016 Hens et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
HIV-1 is considered to be one of the most widespread 
viruses, with 37 million people globally living with HIV-1 
in 2014 and prime endemic areas situated in South and 
East Sub-Saharan Africa [1]. Nonetheless, the sexual 
transmission efficacy of HIV-1 is remarkably lower com-
pared to other viruses (0.01–0.001  %) and is influenced 
by a variety of viral, immunological, physical and behav-
ioral factors. Especially the innate immune response in 
the genital mucosa seems to affect the HIV-1 transmis-
sion efficacy, as it is capable of inducing a swift antiviral 
immune response against both free and cell-associated 
viruses (reviewed in [2]). A successful infection by HIV-1 
is mostly established (in 80 % of all HIV-1 infections) by 
the transmission of a single viral clone, which exposes 
a weakness of HIV-1 transmission [3]. Therefore, an 
immune response targeting these clones is more likely 
to prevent infection compared to other stages in HIV-1 
transmission or infection.
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Natural killer (NK) cells are part of the innate immune 
system and are considered to be the main virally 
infected- and tumor cell killing units of this branch of the 
immune system. Furthermore NK cells are also present 
as resident cells in the vaginal, uterine and gut mucosa; 
forming a rapid first line of defense against incom-
ing pathogens (reviewed in [4]). Accordingly, NK cells 
are associated with protection against a variety of viral 
infections including HIV-1. In order to develop a better 
understanding of the resistance pathways where NK cells 
may play a significant role, an adequate study population 
is required. In this respect, HIV-1 exposed seronegatives 
(ESN) comprise a population with remarkable resistance 
to HIV-1 transmission, despite being constantly at risk.
NK cells are displayed as promising mediators of HIV-1 
protection. Studies examining ESNs or slow progressors 
linked the beneficial effect with certain key features of 
NK cell activation, the killer immunoglobulin-like recep-
tor (KIR) on NK cells and its ligand the human leukocyte 
antigen-class I molecules (HLA) on the target cells. Dif-
ferences in KIR/HLA associations related to resistance to 
HIV-1 (HIV-1 resistance) or disease progression accen-
tuate the complexity of interactions with HIV-1 infected 
target cells [5]. Furthermore, NK cell-mediated HIV-1 
resistance was dependent of the HIV-1 donor during sex-
ual transmission, suggesting a role for NK cell responses 
against “non-self” or “allogeneic” target cells [6].
Natural killer cells
One of the protagonists of the innate immune response 
is the natural killer (NK) cell, phenotypically character-
ized by its expression of CD56 and CD16 on the cell 
membrane [7]. Based on this expression NK cells can 
either be labelled “cytotoxic” (CD56dim NK cells), pre-
dominantly producing perforin and granzyme B; or 
“immune-regulatory” (CD56bright NK cells), secreting 
IFN-γ, TNF-α, IL-10, IL-13 and GM-CSF [8, 9]. This 
NK cell functionality is coordinated by the balance of 
incoming activating and inhibitory signals upon encoun-
ter with a target cell. During this encounter the signals 
originate from a variety of receptor/ligand bonds with 
the target cell [10–17]. NK cells receive inhibitory sig-
nals through inhibitory KIRs (iKIRs) (characterized by 
a long (L) cytoplasmic tail) and CD94-NKG2A. Activat-
ing signals are received through activating KIRs (aKIRs) 
(characterized by a short (S) cytoplasmic tail), as well 
as natural cytotoxic receptors (NCR) (NKp30,-44,-46), 
CD94-NKG2C,-E or NKG2D. KIRs can be further subdi-
vided by the number of extracellular domains: 2D or 3D. 
The inhibitory KIR3DL1 receptors bind human leukocyte 
antigen (HLA)-A and –B molecules carrying the Bw4 
epitope [18]; while KIR2DL1/2/3 receptors bind HLA-C 
molecules with either a C1 or C2 signature [19]. Despite 
reasonable homology between activating and inhibitory 
KIRs, to date, only KIR2DS1 has been shown to have the 
same ligand as its inhibitory counterpart, although with 
lower affinity [20]. Recently however, an HIV-1 peptide-
dependent functional competent bond was demonstrated 
between KIR3DS1 and the Bw4 ligand HLA-B*57:01 [21]. 
With this, a potential vital piece of evidence is delivered 
for the existence of a KIR3DS1-HLA-Bw4 bond, as was 
predicted by epidemiological studies but remained pre-
sumptive by the lack of proof [22–24]. The necessity for 
unconventional, virally-derived peptides in the peptide 
binding groove of KIR3DS1 to mediate a bond suggests a 
similar pattern for the other aKIR-HLA bonds, clarifying 
the current lack of proof for these bonds [22].
Activation of NK cells is directed by the balance of 
incoming inhibitory and activating signals (Fig.  1c). 
More specifically, mature NK cells in the absence of 
their self-HLA ligand (missing self ) lowers their activat-
ing threshold and become sensitive for the presence of 
activating ligands (induced or altered self ) expressed by 
virally infected or tumor transformed target cells. Alter-
natively, activation of NK cells can also be achieved when 
the magnitude of the activating signal(s) overwhelms 
the dominant inhibitory signal [25]. Further research on 
the “missing self” model revealed a mechanism called 
“licensing” or “education”, which takes place during NK 
cell maturation and profoundly influences the function-
ality of the matured NK cell. This licensing process allo-
cates functionality towards NK cells capable of creating 
a bond between iKIR and self-HLA during maturation 
(Fig.  1a). Absence of such a bond will result in incom-
petent NK cells also called “hypo-responsive NK cells”. 
These “rules” will preserve tolerance towards healthy, 
self-HLA expressing cells, while ensuring NK cell respon-
sivity towards peptide-altered or self-HLA deficient 
virally-infected or transformed target cells [26–32]. Acti-
vating KIRs, by contrast, were not known to play a role 
in NK cell education, up until Fauriat et al. [33] demon-
strated an inverse NK cell education mechanism directed 
by KIR2DS1 (Fig.  1b). Licensing of KIR2DS1+ NK cells 
was paradoxically only attained in the absence of the 
corresponding HLA-C2 ligand, whereas presence of the 
HLA-ligand generated hypo-responsive NK cells. This 
newly identified education mechanism complements the 
inhibitory counterpart in preventing autoimmunity and 
in recognition of altered HLA class I molecules by NK 
cells [34, 35]. Of note, education of NK cells does not 
result in lifelong functionality, but will constantly adapt 
to the present cellular environment, meaning that NK 
cells who were once hypo-responsive can become func-
tional again and vice versa [36, 37].
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Autologous NK cell activity against HIV‑1 infected 
cells
Influence of HIV‑1 infection on NK cell activity
The presence of the CD56neg NK cell subset during HIV‑1 
infection
In healthy subjects, NK cells are divided into two sub-
sets: CD56bright (~10 % of total NK cell population) and 
CD56dim (~90  % of total NK cell population) NK cells; 
though a third subset is present in negligible frequencies: 
the dysfunctional CD56neg NK cell subset [38]. During 
acute HIV-1 infection, a pathological NK cell redistri-
bution from CD56dim towards CD56neg NK cells is per-
ceived, accompanied by aberrant NK cell functioning 
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Fig. 1 NK cell education and activation pathways. NK cell education can be mediated by iKIRs (KIR2DL1) as well as aKIRs (KIR2DS1) expressed at the 
immature NK cell membrane. In case of education by iKIR (a), a bond between iKIR and self-HLA is necessary to develop fully functional NK cells, 
whereas its absence abrogates NK cell education resulting in hypo-responsive NK cells. In contrast, in aKIR mediated education (b) is the absence of 
the aKIR-ligand necessary for the licensing of immature NK cells, whereas its presence will generate hypo-responsive NK cells. KIR/HLA interactions 
also play a pivotal role in the activation of NK cells (c). Tolerance (red minus) can be mediated by the presence of an inhibitory receptor (Inh-R) -HLA 
bond and the absence of an activating impulse (red minus) (c.1.) or solely by the absence of an activating signal (c.2). However in the absence of the 
Inh-R-ligand bond (“missing self”) an activating NK cell receptor (Act-R) binding non-HLA class I ligands (Act-L) (“induced self”) suffices to induce 
a cytotoxic NK cell response (green plus) (c.3). NK cell activation is also provoked in the presence of viral/tumor peptides in the HLA class I binding 
groove of target cells, benefitting the HLA class I-binding affinity of aKIRs (“altered self”) at the expense of iKIRs (“missing self”) (green plus) (c.4)
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cells is the result of the reduced expression of activating 
receptors (aKIRs and NCRs), an increase in expression 
of inhibitory NK cell receptors and reduced secretion of 
cytokines (IFN-γ, TNF-α and GM-CSF) [40–42]. NK cells 
are affected by high and chronic viremia, which impairs 
their antiviral functioning, ultimately contributing to the 
disease progression [39]. This redistribution is directly 
associated with viral replication, despite the inability of 
HIV-1 to infect NK cells. Suppression of viral replication 
by anti-retroviral therapy is associated with restoration 
towards the normal NK cell subset distribution, sug-
gesting that the impact of HIV-1 on NK cell distribution 
could be reversible [43]. In vitro/vivo administered IL-2 
has also been shown to contribute to the restoration of 
NK cell subset distributions [39, 44].
HIV‑1 impaired dendritic cell functioning limits NK cell 
cytotoxicity
During acute HIV-1 infection, NK-dendritic cell (DC) 
crosstalk could be of vital importance for producing an 
efficient and competent immune response by amplify-
ing the inflammatory potency of the innate and subse-
quently the adaptive immunity. Nevertheless, HIV-1 has 
a negative impact on both these cell types. The expand-
ing CD56neg NK cell subset reduces the capacity of NK 
cells to lyse immature DC (iDC) in order to avoid defi-
cient T cell priming, a process called “DC-editing” [39, 
45]. CD56neg NK cells also have a reduced production of 
IFN-γ and TNF-α, which are necessary for DC matura-
tion [39, 40]. HIV-1 infection directly impacts DC func-
tioning as they produce less IL-12, -15 and -18 during 
acute HIV-1 infection, leading to less IFN-γ production 
by NK cells which retrospectively results in poor DC 
maturation. However, DC cytokine production can be 
restored in HIV-1 patients after receiving anti-retroviral 
therapy [39]. Finally, the chronic phase of HIV-1 infec-
tion is characterized by an increased secretion of IL-10. 
IL-10 induces the generation of tolerogenic DCs using 
direct (by modulating maturation) [46] and indirect (by 
switching DC editing from iDC to matured DC) [47] 
mechanisms. In summary, HIV-1 infection impairs NK 
and DC function and, as a consequence, their crosstalk; 
leading to feeble, non-specific and aberrant immunity.
HIV‑1 uses accessory proteins to escape NK cell recognition
HIV-1 impairs NK cell function and escapes recognition 
by the expression of accessory proteins. These intracellu-
lar proteins (in)directly disturb NK cell activity by affect-
ing a wide variety of immunological pathways. The HIV-1 
protein “Nef” is able to down-regulate HLA class I mol-
ecules on the surface of infected cells [48]. Downregula-
tion of HLA class I molecules may prevent recognition 
by CD8+ T-cells, but might render these cells vulnerable 
for NK cell mediated lysis by absence of an iKIR-HLA 
bond. However, Nef evades NK cell activation by selec-
tively sparing KIR ligands HLA-C and HLA-E, while 
mainly the CD8+ T-cell receptor ligands HLA-A and to 
a lesser extent HLA-B are downregulated [49–51]. In 
other words, Nef-induced HLA class I downregulation 
results in the partial evasion of T- and NK cell recogni-
tion of HIV-1. The viral proteins Tat and Vpu are also 
able to downregulate HLA class I molecules, though be it 
by the blockage of distinct steps in the synthesis of HLA 
molecules [52, 53]. Furthermore, these viral proteins can 
also undermine NK cell functioning by denying activa-
tion through activating receptors [54–56] and impairing 
crucial interactions between DC and NK cells [57, 58]. 
Clearly, the HIV-1 accessory proteins dampen the virally 
infected phenotype of the host cell and try to mimic the 
behavior of normal healthy cells in an attempt to avoid 
recognition by the immune system, including NK cells. In 
this way HIV-1 manages to fool both the primary and the 
secondary line of viral defense with only a few proteins.
NK cell activity during HIV‑1 infection
During acute HIV-1 infection, DC-secreted cytokines 
(IFN-α and IL-15) activate, arm and expand the NK cell 
population in an attempt to constrain viral replication 
by NK cell mediated killing [59]. HIV-1 developed mul-
tiple evasion strategies (mentioned above) which impair 
NK cell activation. This feature of HIV-1 indicates that 
the pressure exerted by NK cells threatens the survival 
of the virus [60]. This is illustrated by the many associa-
tions between slower progression towards the acquired 
immune-deficiency syndrome (AIDS) in slow HIV-1 pro-
gressors and certain characteristics of NK cells. These 
characteristics are mostly related to improved NK cell 
recognition, which directly influences NK cell activity. 
Multiple examples highlighting the pressure and influ-
ence that NK cells exert on HIV-1 infection will be listed 
in the following paragraphs (Table 1).
NK cells influencing HIV‑1 disease progression
As NK cell activation is mainly controlled by KIR and 
HLA molecules, it is plausible that certain KIR and HLA 
alleles would be associated with a slower disease pro-
gression towards AIDS. The following paragraph will 
discuss the potential of KIR3DS1,-L1,-2DL1-4 receptors 
and anti-HIV-1 antibodies (Ab) in improving disease 
outcome.
The influence of activating receptors The intra-individual 
genetic combination KIR3DS1/HLA-Bw4-80I (HLA-Bw4 
antigen with isoleucine at position 80) is well-known for 
its association with slower disease progression [59]. Evi-
dence of improved in vitro viral suppression and expan-
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Table 1 KIR and HLA genotypes related to HIV‑1 outcome
Summarization of the KIR, HLA or KIR-HLA haplo-/genotypes associated with HIV-1 resistance and disease progression towards AIDS. HLA class I genotypes associated 
with altered HIV-1 outcome are not included as its function is not solely relevant for NK cell responses but also for CD8+  T cell responses. Additional data in Table 1 
obtained from [123] and [124]
HIV‑1 outcome Receptor/ligand Mechanism Ref
HIV-1 resistance KIR3DS1/S1 HLA-Bw4 No/less inhibition and increased activation, promoting faster NK cell 
activation
[85, 86]
KIR3DS1/x HLA-Bw4 No/less inhibition and increased activation, promoting faster NK cell 
activation
[87]
KIR3DS1/L1 Higher activating ratio, stronger NK cell response [84]
KIR3DL1*h HLA-B*57 “Amplified” education, resulting in stronger NK cell response in absence 
of ligand
[72]
KIR3DL1 Bw4 Educated KIR3DL1+ NK cells had increased anti-HIV-1 ADCC mediated 
cytotoxicity against allogeneic target cells
[76]
KIR3DL1 HLA-Bw6/Bw6 Absence/lowering of inhibitory threshold, promoting faster NK cell 
activation
[88]
KIR2DL2/3 HLA-C2/C2 Absence/lowering of inhibitory threshold [88]
KIR2DS4del Unknown Unpublished
KIR2DL1 HLA-C2 Absence of HLA-C2 expression by allogeneic target cells induces cyto-
toxicity based on KIR/HLA mismatch
[6]
Haplotype B/x Multiple aKIRs inducing stronger response [6, 84–88]
Slower disease progression KIR3DS1 HLA-Bw4-80I Slower disease progression; Robust expansion during early infection; 
Inhibition in vitro viral replication
[59–61]
Increase of copy numbers is associated with inhibition of viral replication [62]
In vitro production of viral inhibiting chemokines (CCL3-5), preventing 
HIV-1 entry
[123]
KIR3DS1 HLA-B*57/58 Lower CD38-expression, increased degranulation and IFN-γ production [64]
KIR3DS1 Associated with higher CD4+ T-cell counts [63]
KIR3DL1/S1 HLA-Bw4 KIR3DL1-dose dependent-licensed NK cells exert cytotoxicity via 
KIR3DS1-mediated activation
[66]
KIR3DL1 HLA-Bw4 Increased polyfunctionality by KIR3DL1 licensed NK cells [65]
Educated KIR3DL1+ NK cells had increased anti-HIV-1 ADCC mediated 
activation
[75]
KIR3DL1*h HLA-Bw4-80I Delayed progression to AIDS, increased degranulation, TNF and IFN-γ 
production
[66, 67]
KIR3DL1*h HLA-B*57 “Amplified” education, resulting in strong NK cell response, increased NK 
cell trifunctionality
[66, 68, 69]
In vitro production of viral inhibiting chemokines (CCL3-5), preventing 
HIV-1 entry
[123]
KIR3DL1*004 HLA-Bw4 Absence/lowering of inhibitory threshold, because of intracellular 
expression of KIR3DL1
[66]
KIR2DL3 HLA-C1 Lower viral load and higher CD4 count associated with HIV-1 specific NK 
cell responses
[73]
KIR2DL4 CD4+ T-cell preservation, higher copy number resulting in increased 
IFN-γ production in SIV-infection
[124]
Rapid disease progression KIR3DS1 HLA-Bw4-80I Rapid progression, no education of KIR3DS1 expressing NK cells [80]
KIR3DS1(/S1) Rapid progression, robust immune activation accelerating disease 
progression
[59, 80]
KIR2DS2/3 Rapid progression, robust immune activation accelerating disease 
progression
[80]
KIR2DS4*001 High viral load and accelerated HIV-1 transmission, immune activation 
accelerating disease progression
[82]
KIR2DL2/3 HLA-C1 Higher viral load and increased mortality [83]
Haplotype B/x Rapid progression, robust immune activation accelerating disease 
progression
[80, 81]
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sion during acute primary HIV-1 infection of KIR3DS1+ 
NK cells in HLA-Bw4-80I bearing individuals supports 
the beneficial effect of KIR3DS1+ NK cells on HIV-1 pro-
gression [60, 61]. However, the actual pathways used to 
activate and license these NK cells are still point of debate. 
As mentioned previously, the binding of KIR3DS1 with 
HLA-Bw4 is not fully proven and activation might depend 
on viral peptides bound by HLA-Bw4-80I [21]. In anal-
ogy to the KIR2DS1-licensing pathway (mentioned above) 
[33], where the presence of KIR2DS1 with corresponding 
ligand HLA-C2 will not result in licensing, functional-
competent KIR3DS1+ NK cells would therefore have to 
be licensed by co-expressing iKIRs [62]. In contrast, the 
sole carriage of KIR3DS1 was also associated with slower 
disease progression. In this situation, KIR3DS1+ NK cells 
could be educated to their full competence, in resem-
blance with the KIR2DS1-licensing pathway [63, 64]. In 
conclusion, it is clear that KIR3DS1+ NK cells dampen 
HIV-1 progression, though the activation and licensing 
mechanisms remain unclear.
The influence of  inhibitory receptors The inhibitory 
counterpart of KIR3DS1, KIR3DL1, is characterized by 
highly polymorphic alleles which leads to high variabil-
ity in the expression of KIR3DL1. HIV-1 slow progres-
sors and elite controllers who possess KIR3DL1 alleles 
resulting in high expression (KIR3DL1*h) and HLA-
Bw4-80I had increased NK cell functionality [65–69]. 
The enhanced NK cell functionality seen in the pres-
ence of these KIR3DL1*h alleles can be explained by 
another feature of licensing supported by the “rheostat 
model”. The intensity of licensing is dose-dependent, in 
which an increased amount of iKIR-self-HLA bonds will 
lead to stronger licensing and result in a stronger reac-
tion in its absence [70, 71]. Additionally, co-expression 
of an KIR3DL1*h allele with HLA-B*57 not only slowed 
disease progression, but also induced a protective effect 
against HIV-1 acquisition [72]. Licensed KIR2DL1-3 NK 
cells were also associated with slower disease progression 
as they largely contributed to NK cell functionality and 
were seen to expand in early HIV-1 infection [73]. Specific 
HIV-1 peptide NK cell responses were largely mediated 
by licensed KIR2DL3+/C1+ patients with the support of 
a more activating oriented KIR phenotype (B haplotype) 
[74]. Similar results were previously described in Hepati-
tis C virus (HCV) infection [75]. The HIV-1/HCV protec-
tive effect can be explained by the low binding affinity of 
KIR2DL3 for HLA-C1, compared to KIR2DL2, resulting 
in a lower threshold for activating ligands to overrule inhi-
bition subsequently leading to NK cell activation. Lastly, 
anti-HIV-1 Ab are able to guide NK cells towards target 
cells by binding to the Fc-receptor CD16 on NK cells. 
This bond also provides an additional activating signal, 
which contributes to overcome the inhibitory threshold 
[76]. Anti-HIV-1 Ab improve the HIV-1 defensive capaci-
ties of NK cells which was found to result in a lower viral 
set point and a slower disease progression [77, 78]. The 
actions of anti-HIV Ab in aiding NK cell cytotoxicity can 
be grouped and named as antibody-dependent cell cyto-
toxicity (ADCC) [79–82].
Accelerated disease progression In contrast to the afore-
mentioned beneficial genotypes, certain KIR and/or HLA 
genotypes were also seen to accelerate disease progres-
sion. KIR3DS1, both with [83] and without [59] HLA-
Bw4-80I has been associated with accelerated disease pro-
gression. Likewise, other aKIRs [83–85] were also related 
to a detrimental HIV-1 outcome. Similarly, Ebola infected 
patients possessing the aKIR genes KIR2DS1 and -3 were 
associated with fatal outcome [86]. It is possible that 
NK cells with an activating KIR profile would preferably 
generate a pro-inflammatory environment, compared to 
more inhibitory “tolerable” NK cells. We suggest that this 
pro-inflammatory environment will contribute to chronic 
immune activation and attraction of target cells, acceler-
ating disease progression. Recent findings also associated 
co-carriage of KIR2DL3 and HLA-C1 with higher viral 
load and increased mortality rates [87]. Although this was 
previously seen to be favorable in HIV-1 and HCV infec-
tion, it is in line with the previous findings as activation 
defined NK cells are more plausible to accelerate disease 
progression [74, 75].
NK cell functioning in HIV‑1 resistance
In the search for HIV-1 resistance mechanisms, ESN 
are often investigated as population of interest. ESNs 
are exposed to HIV-1 but remain seronegative, suggest-
ing that they are resistant to HIV-1 infection. Functional 
studies of a Vietnamese ESN cohort first demonstrated 
an increase in activated NK cells [88]. Genetic epidemio-
logical studies of African ESN cohorts later found acti-
vation oriented KIR/HLA genotypes, consisting of KIR 
B haplotype and iKIRs in the absence of their ligands 
(KIR2DL2/3-HLA-C2 and KIR3DL1-HLA-Bw6) to be 
associated with resistance to HIV-1 ([89] and later con-
firmed in ref [6]). The authors hypothesized that the 
absence of the inhibitory iKIR/HLA signal would lower 
the NK cell activation threshold which would result in a 
faster NK cell activation upon encounter with activating 
ligands on infected target cells. Similarly, the presence 
of KIR2DL3 in combination with HLA-C1, resulting in 
a lower activation threshold and accelerated activation 
eventually; was associated with slower disease progres-
sion [74] as well as HIV-1 resistance [90]. The hypothesis 
of an accelerated NK cell activation in ESNs was strength-
ened by epidemiological data on KIR3DS1 (haplotype B) 
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in ESNs. Multiple studies ascribed the protective effect 
in ESNs to the increased or decreased prevalence of 
KIR3DS1 and KIR3DL1 respectively [90–93]. The ele-
vated KIR3DS1/L1 ratio seen in these ESN cohorts, how-
ever, was not always in association with HLA-Bw4 [90, 
91]. These results might rather highlight the beneficial 
effect of an activating KIR haplotype in general, instead 
of the specific KIR3DS1-HLA-Bw4 bond. Exceptionally, 
in an ESN cohort consisting of hemophilia A patients, no 
KIR or HLA allele was correlated with HIV-1 protection. 
However, absence of this association could be ascribed 
to the influence of the far more infectious parental trans-
mission route, potentially overruling the effect of KIR 
and HLA on transmission which is seen to be correlated 
with HIV-1 resistance in sexual transmission [94]. In 
summary, HIV-1 resistance can be related to more “reac-
tive” NK cells, be it by the increase of aKIRs or the lower-
ing of the activation threshold.
Interpretation of NK cells influencing HIV‑1 resistance 
and disease progression
In an attempt to order and structure all the informa-
tion regarding the influence of NK cells on HIV-1 infec-
tion and transmission, we will discuss the findings in 
the previous paragraphs. In multiple in vivo and in vitro 
studies, the effect of KIR3DS1+ NK cells in combina-
tion with HLA-Bw4 on HIV-1 infection was seen to 
result in slower disease progression. These data suggest 
that these KIR3DS1+ NK cells become activated during 
acute HIV-1 infection, potentially by the presentation of 
HIV-1 peptides on the HLA-Bw4 molecules. In contrast, 
KIR3DS1 is also associated with an accelerated disease 
progression. In addition, data correlating other aKIRs 
and a lower activation threshold with a detrimental out-
come, suggests that the activation oriented KIR profile 
is responsible for the accelerated rather than a slower 
disease progression. Though this data is less convinc-
ing than the evidence concerning KIR3DS1+ NK cells 
being related to slower disease progression, it is sup-
ported by similar results in Ebola infection and should 
be taken into account when describing NK cell responses 
in HIV-1 infection. Genetic data of ESNs suggest a ben-
eficial effect of KIR3DS1+ NK cell on the induction of 
HIV-1 resistance. In general, HIV-1 resistance has been 
associated with NK cells who are prone to activation, by 
an increased prevalence of aKIR or by the lowering of the 
activation threshold.
In conclusion, we propose an alternative hypothesis, 
irrespective of the well-known beneficial KIR3DS1+ NK 
cell effect on disease progression. If the early pro-inflam-
matory NK cell burst does not suffice to eliminate HIV-
1, NK cells in possession of a more activation-oriented 
KIR B haplotype will paradoxically accelerate HIV-1 
spread and disease progression by attracting target cells 
and contributing to chronic immune activation. On the 
other hand, NK cell responses in individuals with a more 
inhibition-oriented KIR A haplotype will be less inflam-
matory and will be able to dampen HIV-1 spread and 
disease progression once HIV-1 mediated HLA class I 
down-modulation tends to take place.
The benefit of NK cells in haplo‑hematopoietic 
stem cell transplantation
Although debate is ongoing, HIV transmission mediated 
by cell-associated virus is believed to be more efficient 
than transmission mediated by free virus. In  vitro and 
in vivo analysis of SIV-transmission efficacy [95–97] con-
firmed the competence and successfulness of cell-medi-
ated HIV-1 transmission (reviewed in [98]). Together 
with the presence of mucosal NK cells, the inter-individ-
ual HLA class I variability and the multiple HIV-1 resist-
ance associations might suggest a direct NK cell response 
against incoming allogeneic HIV-infected cells. The effec-
tiveness of these “alloreactive” NK cells is already verified 
in immunotherapy applied in acute myeloid leukemia 
and acute lymphoid leukemia: haploidentical-hematopoi-
etic stem cell transplantation (haplo-HSCT).
The clinical relevance of alloreactive NK cells in haplo‑HSCT
A haplo-identical donor and its recipient share one iden-
tical HLA-haplotype and differ at the HLA class I and II 
locus of the other haplotype. In HLA-identical HSCT, 
T-cells mediate the graft-versus-leukemia (GVL) effect, 
enhance engraftment and reconstitute immunity. But 
T-cells in an allogeneic environment become reactive 
and first need to be extensively depleted from the haplo-
HSCT graft to avoid graft-versus-host disease (GVHD). 
Remarkably, the GVL effect in T-cell depleted haplo-
HSCT was handed over to alloreactive NK cells driven 
by a KIR/HLA mismatch [99, 100]. Also “megadoses” of 
CD34+ stem cells are used for transplantation to promote 
donor-derived immune recovery and to help overcome 
graft rejection induced by recipient’s anti-donor cyto-
toxic T-cells (reviewed in [101]). CD34+ stem cell mega-
doses also create a donor-like derived environment in the 
recipient, resulting in donor HLA-based NK cell educa-
tion [27, 102]. To date, NK cells are capable of remaining 
alloreactive for more than 5  years after transplantation 
[103, 104].
Favorable KIR/HLA interactions in haplo‑HSCT
NK cell alloreactivity in haplo-HSCT is only guaranteed 
for licensed ‘missing self ’ KIR/HLA combinations spe-
cifically consisting of donor inhibitory KIR that recognize 
HLA allotypes present in the donor but which are lacking 
in the recipient [102]. In addition, absence of the inhibitory 
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CD94/NKG2A was also necessary as its ligand, HLA-E, 
is expressed on all HLA class-I expressing cells [99, 103]. 
The presence of the activating B haplotype in an acute 
myeloid leukemia cohort was also found to be related to 
a low risk of leukemic relapse and prolonged survival 
[105]. Moreover, different aKIRs have proven their value in 
haplo-HSCT, as KIR3DS1 and KIR2DS2 were associated 
with mild acute GVHD and decreased leukemic relapse, 
respectively [106, 107]. KIR2DS1+ NK cells have shown 
to lyse C2+ leukemia cells, capable of overriding a thresh-
old composed by different inhibitory signals, decreasing 
GVHD and redirecting the NK cells towards the lymphe 
nodes [103, 108–112]. Given these results, KIR2DS1 co-
expression on donor-derived NK cells is a major contribu-
tor to the alloreactivity of NK cells and is already seen as 
one of the more important parameters in the calculation of 
the alloreactive NK cell subset size. Besides killing recipi-
ent DCs, alloreactive NK cells also kill residual recipient 
T-cells, preventing host versus graft (HvG) responses, 
which results in adequate engraftment [112].
The discovery of alloreactive NK cells as the major 
allo-effectors in haplo-HSCT is one of the largest break-
throughs in the recent history of treating leukemia. Allo-
reactive NK cells have the potential to further improve 
leukemia therapy with less invasive and burdensome 
techniques. In relation to HIV-1 infection, certain paral-
lels can already be drawn between HIV-1 resistant and 
haplo-HSCT NK cell characteristics, such as the benefi-
cial effect of an activating B haplotype and the presence 
of aKIRs. The haplo-HSCT field precedes the HIV-1 
field in terms of knowledge about alloreactive NK cell 
responses. Therefore, it is useful to take these results in 
regard when investigating alloreactive NK cells and its 
role in HIV-1 resistance.
Alloreactive NK cells in HIV‑1 infection
A reasonable amount of HIV-1 research is focused on 
the innate immune system, and more specifically on 
the relationship of KIR and HLA variability with HIV-1 
resistance or disease progression. In most cases only the 
recipient’s characteristics are taken into account, whereas 
NK cells are also able to mediate allogeneic responses, as 
is seen in haplo-HSCT (explained in “The benefit of NK 
cells in haplo-hematopoietic stem cell transplantation” 
section). In the following paragraphs, existing evidence of 
alloreactive NK cells playing a role in resistance to HIV-1 
is summarized.
Alloreactive NK cells in sexual HIV‑1 protection
Jennes et al. recently investigated a cohort of HIV-1 dis-
cordant couples (dC) from Dakar, Senegal, consisting of 
one HIV-1− and one HIV-1+ partner [6]. The study first 
of all confirmed known associations of activating KIR 
genotypes and inhibitory KIRs in absence of their HLA 
ligands with HIV-1 resistance [89]. In addition, a specific 
mismatched allogeneic KIR/HLA combination, consist-
ing of recipient KIR2DL1/HLA-C2 with donor HLA-C1/
C1, was found increased in the HIV-1 dC group com-
pared to the concordant (i.e. when both partners were 
HIV-1+) group. Conversely, a specific matched allo-
geneic combination, consisting of recipient homozy-
gous KIR2DL3 with donor HLA-C1/C2, was found 
increased in the HIV-1 concordant group compared to 
the dC group. In theory, the allogeneic KIR/HLA mis-
match generates a missing-self context, whereby the 
expression of ligands for activating NK cell receptors on 
HIV-1 infected donor cells would induce “alloreactive” 
responses by recipient NK cells. In contrast, a matched 
allogeneic KIR/HLA combination contributes to the 
inhibition of alloreactive NK cell responses. In vitro co-
cultures of healthy donor NK cells with CD4+ T-cells 
derived from HIV-1 patients were performed to investi-
gate the magnitude of the allogeneic NK cell responses. 
A clear increase in CD4+ T-cell death was seen in the 
presence of an allogeneic KIR/HLA mismatch [6]. These 
results support the hypothesis of the presence of HIV-1 
protective alloreactive NK cell responses. Similar in vitro 
studies with an increased sample size are now being 
carried out by our research group in an attempt to con-
firm and further unravel the mechanisms behind these 
responses.
Alongside KIR and HLA, NK cell mediated ADCC 
is regarded as an additional mechanism capable of lys-
ing HIV-1 infected CD4  +  T-cells [80, 82]. Although 
HIV-1 ESNs do not possess anti-HIV-1 IgG antibodies, 
it has been shown that IgG transmission from HIV-1 
infected mothers to their children during breastfeeding 
rendered these children HIV-1 resistant [113]. Recently, 
anti-HIV-1 antibodies capable of triggering ADCC were 
detected in the seminal plasma and vaginal fluid of HIV-1 
patients [114, 115]. ADCC was preferably generated by 
educated NK cells expressing KIR2DL1 and HLA-C2 
[82], similar to the results of Jennes et  al. [6] where the 
combination of a KIR2DL1/HLA-C2 recipient with an 
HLA-C1 donor was elevated in the ESN cohort. There-
fore we suggest that in the presence of an allogeneic KIR/
HLA mismatch (seen in [6]), resulting in a lower activa-
tion threshold, anti-HIV-1 Ab can further activate NK 
cells by binding its activating NK cell Fc-receptor CD16 
(seen in [82]). Anti-HIV-1 Ab might preferentially induce 
NK cell alloreactivity as it is not affected by the HIV-1 
impaired expression of activating ligands, guaranteeing a 
competent signal. Furthermore, these anti-HIV-1 Ab are 
capable of binding HIV-1 infected cells as well as cell-free 
virions, providing a complete screening for HIV-1 prior 
to exposure during transmission.
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Alloreactive NK cells during vertical HIV‑1 transmission
HIV-1 infected pregnant women are capable of trans-
mitting the virus to their child during gestation, deliv-
ery, or breast-feeding. Mother–child interactions can be 
seen as allogeneic interactions as the child has only one 
identical haplotype, haplo-identical, with the mother. 
In analogy with multiple HIV-1 studies investigating 
ESNs [6, 89–92], the frequency of activating KIR pro-
files was significantly increased in non-transmitting 
mothers compared to transmitting mothers [116]. Con-
versely, an elevated frequency of allogeneic KIR/HLA 
matches (infantKIR2DL2/2DL3- motherHLA-C1/C1) 
was observed among HIV-transmitting mother/infant 
pairs [117], confirming the increased frequency of the 
matched allogeneic KIR/HLA combination among Sen-
egalese HIV-transmitting concordant couples [6]. In 
multiple studies, vertical as well as sexual HIV-1 trans-
mission was found associated with sharing of HLA class 
I alleles between mother and child or between part-
ners [118–121]. In other words, transmission is most 
likely to occur when educated NK cells are silenced by 
a KIR/HLA match, resulting in a more HIV-1 receptive 
environment.
Future perspectives
Mucosal NK cells are present in the female reproduc-
tive tract, from the uterus to the vagina, as well as the 
gastro-intestinal tract, and express an immature pheno-
type (reviewed in [4]). Studying the local maturational, 
migratory and cytotoxic capabilities of mucosal NK cells 
during HIV-1 transmission will help to calculate the con-
tribution of mucosal NK cells in HIV-1 resistant immune 
responses. Macaques are an ideal model for these experi-
ments and were already essential for revealing different 
in  vivo migration routes and immune responses during 
early HIV-1 infection (reviewed in [122]). In addition, 
the use of HIV-1 dC couples is very suitable to study the 
impact of the alloreactive mechanism on HIV-1 acquisi-
tion. A decent number of studies on HIV-1 dC cohorts 
did not investigate NK cell alloreactivity. Data from these 
studies could possibly be reanalyzed with a renewed 
focus on allogeneic KIR/HLA relations between both 
partners. In this way, new data can be generated to add 
to the small amount of existing information on the role 
of NK cell alloreactivity in HIV-1 resistance. Also the 
contribution of anti-HIV-1 ADCC towards NK cell acti-
vation is an interesting element that needs to be further 
explored, specifically in the allogeneic context. Nonethe-
less, studies focusing on NK cell function in the context 
of HIV-1 often investigate populations that have a high 
burden of viral co-infections. Since infections, such 
as Cytomegalovirus, are known to influence NK cell 
function, future studies should take this possible limita-
tion into account.
Conclusion
The HIV-1 epidemic has grown out to be one of the most 
widespread infectious diseases in the world. However, 
some individuals seem to resist infection with HIV-1, 
despite repeated exposure to the virus. Throughout the 
years, different cohorts have been assembled, consisting 
of such HIV-1 exposed uninfected individuals. These so-
called ESNs constitute an interesting population for the 
study of HIV-1 protective mechanisms in an attempt to 
develop HIV-1 preventive or curative therapies. Impor-
tantly, HIV appears to be extremely vulnerable to the 
host immune responses during a brief time frame imme-
diately after sexual exposure to HIV-1. This finding 
resulted in a rediscovered interest for the innate immu-
nity, with NK cells as potential HIV-1 restrictive effector 
cells. NK cells have not only been linked to HIV-1 resist-
ance but are also found to influence disease progression, 
although some results indicate that different and even 
opposing mechanisms might be involved. Examining 
the protective effects in HIV-1 dC couples revealed KIR/
HLA mismatches between both partners, suggesting an 
HIV-1 protective mechanism orchestrated by alloreactive 
NK cells, whose usefulness has already been proven in 
the treatment of leukemia.
In summary, an increasing amount of evidence 
seems to suggest an important role for alloreactive NK 
cell responses in resistance to HIV-1 infection. These 
responses likely take place during the transmission time-
frame where HIV-1 is most vulnerable, before the immu-
nological influence of established HIV-1 infection can 
take effect. This mechanism likely involves an allogeneic 
KIR/HLA mismatch which triggers the missing self-
mechanism. Still, further research is needed to explore 
the full potential of NK cells as protective mediators dur-
ing sexual HIV-1 transmission. Retrospective reanalysis 
of existing HIV-1 dC cohort data in particular could pro-
vide valuable insight into these protective mechanisms. 
Even so, current findings seem promising and could per-
haps 1 day lead to a preventive immunotherapy based on 
the alloreactive NK cell principle.
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